Trial Profile

A Phase 1 First-in-human study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NY-ESO-1 TCR-T cell therapy (Primary) ; Cyclophosphamide; Fludarabine
Indications Myxoid liposarcoma; Synovial sarcoma
Focus Adverse reactions; First in man

Most Recent Events

18 Dec 2023 According to Replay media release, this study is expected to start in in Q4 of this year.
22 Jun 2023 New trial record
20 Jun 2023 According to Replay media release, this study is anticipated to start in Q3 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com